Iradimed Corp Stock Price, News & Analysis

IRADIMED CORPORATION (NASDAQ: IRMD) has announced a special cash dividend of $1.00 per share, payable on February 24, 2022, to shareholders of record by February 17, 2022. This decision reflects the company's strong financial performance, with a cash reserve of nearly $62 million at the end of 2021. The Board aims to return excess cash to its shareholders while ensuring operational and investment needs are met.

iRadimed Corporation (NASDAQ: IRMD) reported fourth-quarter 2021 revenue of $11.9 million, a 39% increase from the previous year, with net income at $3.9 million or $0.31 per diluted share. For the full year 2021, revenue reached $41.8 million, up 32%, with net income of $9.3 million or $0.74 per diluted share. The company anticipates revenue guidance for 2022 between $51.4 million and $52.2 million and GAAP EPS of $0.82 to $0.90, reflecting continued demand for its MRI-compatible devices despite supply chain challenges.

IRADIMED CORPORATION (NASDAQ: IRMD) will release its 2021 fourth quarter financial results before market opening on February 4, 2022. A conference call is scheduled for the same day at 11:00 a.m. ET to discuss these results and address questions. Interested parties can listen by dialing 1-844-413-1781 or 1-716-247-5767, entering reservation code 2899922. The call will also be streamed live online, with a recording available on the company's website for 90 days post-call.

IRADIMED CORPORATION (NASDAQ: IRMD) reported third-quarter 2021 revenue of $10.9 million, a significant increase from $7.7 million in Q3 2020. The company achieved a GAAP diluted EPS of $0.20 and a non-GAAP diluted EPS of $0.23. For the nine months ended September 30, 2021, revenue reached $29.9 million, up from $23.2 million in the same period of 2020. The company has increased its full-year guidance, anticipating revenue of $41.4 million to $41.6 million and GAAP diluted EPS of $0.60 to $0.61.

IRADIMED CORPORATION (NASDAQ: IRMD) will release its third quarter financial results for 2021 before the market opens on October 29. The management will host a conference call at 11:00 a.m. ET that same day to discuss the results and answer questions. Interested participants can dial 1-844-413-1781 for domestic calls or 1-716-247-5767 for international calls. The call will also be available via the Internet and recorded for 90 days post-call.

IRADIMED CORPORATION (NASDAQ: IRMD) reported second-quarter 2021 revenue of $9.8 million, a significant increase from $6.8 million in Q2 2020. The net income reached $1.5 million, or $0.12 per diluted share, compared to a net loss of $(2.1) million in the same quarter last year. Non-GAAP diluted EPS was $0.14, reflecting a positive trend in earnings. Guidance for Q3 2021 anticipates revenue between $10.3 million and $10.5 million and full-year revenue expectations of $40.0 million to $40.4 million.

IRADIMED CORPORATION (NASDAQ: IRMD) will release its 2021 second quarter financial results on July 30, 2021, before market opening. Management will host a conference call at 11:00 a.m. ET to discuss these results and answer questions. Interested participants can join by calling 1-844-413-1781 domestically or 1-716-247-5767 internationally, using reservation code 7590809. The call will also be available online with a recording accessible for 90 days post-call. IRADIMED is a leader in MRI-compatible medical devices, particularly known for its MRidium IV infusion pump and 3880 monitoring system.

Iradimed Corporation (NASDAQ: IRMD) reported Q1 2021 revenue of $9.2 million, up from $8.7 million in Q1 2020. GAAP diluted EPS was $0.11 compared to $0.14 the previous year, primarily due to a $0.4 million tax expense. Non-GAAP diluted EPS was $0.13, down from $0.18. The company noted a 32% increase in IV pump revenue and 112% growth in income before taxes. Cash and investments totaled $52.7 million as of March 31, 2021. Iradimed refrained from providing financial guidance due to ongoing COVID-19 uncertainties.

IRADIMED CORPORATION (NASDAQ: IRMD) will release its Q1 2021 financial results on April 30, 2021, before market open. A conference call will follow at 11:00 a.m. ET for management to discuss these results and answer questions. Interested parties can listen by calling 1-844-413-1781 domestically or 1-716-247-5767 internationally, using reservation code 8386999. The call will also be streamed online and a recording will be available on the company’s website for 90 days post-call.